HURA - Multiplikator P/S TuHURA Biosciences Inc.

Logo korporat perusahaan TuHURA (HURA)

The EV/Revenue multiple for TuHURA Biosciences, Inc. (HURA) reflects volatile market expectations, with the value serving as the baseline metric. This price action is driven by the complexities of developing anti-tumor vaccines and stringent FDA oversight. Meanwhile, the company's status as an immunotherapy leader bolsters confidence among the scientific community. The current trend depends on the effectiveness of post-merger management integration and the launch of new clinical trial phases.

HURA: Kapitalisasi marang pendapatan tuhurabio.com 04.07.2022 - 15.11.2026

Rincian analitis perusahaan tuhurabio.com (HURA)

- kuotasi lan prakiraan analis:
Ringkesan analitik perusahaan:TuHURA, HURA
Produk dadi TuHURA Biosciences, Inc.

The P/S ratio reflects the market value of a business relative to its revenue, allowing for an assessment of cash flow monetization efficiency without accounting for debt load. For TuHURA Biosciences, Inc. (HURA), given the colossal R&D expenditures and stringent FDA oversight of vaccines, the current P/S ratio helps align market capitalization with actual technology commercialization rates, eliminating emotional bias from the valuation analysis.

Perusahaan pesaing

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|TARA (Protara Therapeutics, Inc.) - Multiplikator P/S|Multiplikator P/S Fate Therapeutics Inc|Multiplikator P/S WHWK|Multiplikator P/S TScan Therapeutics Inc (TCRX)|Rasio rega marang pendapatan championsoncology.com CSBR|XBIT - Kapitalisasi marang pendapatan|CVM - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OSTX (OS Therapies)|RADX: Multiplikator P/S|Artiva Biotherapeutics Inc. - Rasio kapitalisasi pasar marang pendapatan|ANL (Adlai Nortye) - Multiplikator P/S|Multiplikator P/S verupharma.com|Kapitalisasi marang pendapatan TPST (tempesttx.com)|Kapitalisasi marang pendapatan Xilio Therapeutics Inc XLO|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd